Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report)’s stock price rose 9.7% on Monday . The stock traded as high as $0.59 and last traded at $0.59. Approximately 200 shares changed hands during mid-day trading, a decline of 98% from the average daily volume of 11,751 shares. The stock had previously closed at $0.53.
Defence Therapeutics Price Performance
The company’s fifty day simple moving average is $0.50 and its 200 day simple moving average is $0.58.
Defence Therapeutics Company Profile
Defence Therapeutics Inc engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments.
Recommended Stories
- Five stocks we like better than Defence Therapeutics
- What Investors Need to Know About Upcoming IPOs
- Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet
- How to Find Undervalued Stocks
- 3 High-Yield Banks for Investors to Buy on the Dip
- What is a support level?
- 5 Surprising Stocks Set to Benefit From a Future Robotics Boom
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
